Financials

News Discussions Technicals Forecast Seasonals

Diluted net income available to common stockholders of EVER SUPREME BIO TECHNOLOGY CO LTD

Annual data

2017

2018

2019

2020

2021

2022

2023

TTM

‪‪−200.00 M‬‬

‪0.00‬

‪‪200.00 M‬‬

‪‪400.00 M‬‬

‪‪600.00 M‬‬

Period

Value

Change

Change %

TTM

‪‪254.33 M‬‬

‪‪−285.07 M‬‬

‪−52.85‬%

2023

‪‪539.40 M‬‬

+‪‪338.68 M‬‬

+‪168.74‬%

2022

‪‪200.71 M‬‬

‪‪−168.89 M‬‬

‪−45.69‬%

2021

‪‪369.60 M‬‬

+‪‪476.43 M‬‬

—

2020

‪‪−106.83 M‬‬

‪‪−12.61 M‬‬

‪−13.38‬%

2019

‪‪−94.22 M‬‬

‪‪−25.45 M‬‬

‪−37.00‬%

2018

2017

Quarterly data

Q3 '20

Q4 '20

Q1 '21

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

‪0.00‬

‪‪70.00 M‬‬

‪‪140.00 M‬‬

‪‪210.00 M‬‬

‪‪280.00 M‬‬

Period

Value

Change

Change %

Q3 '24

‪‪18.53 M‬‬

‪‪−96.98 M‬‬

‪−83.96‬%

Q2 '24

‪‪115.52 M‬‬

+‪‪93.33 M‬‬

+‪420.69‬%

Q1 '24

‪‪22.18 M‬‬

‪‪−75.91 M‬‬

‪−77.38‬%

Q4 '23

‪‪98.10 M‬‬

‪‪−176.81 M‬‬

‪−64.32‬%

Q3 '23

‪‪274.91 M‬‬

+‪‪224.18 M‬‬

+‪441.93‬%

Q2 '23

‪‪50.73 M‬‬

‪‪−64.93 M‬‬

‪−56.14‬%

Q1 '23

‪‪115.66 M‬‬

‪‪−14.51 M‬‬

‪−11.15‬%

Q4 '22

‪‪130.17 M‬‬

+‪‪91.93 M‬‬

+‪240.40‬%

Q3 '22

Q2 '22

Q1 '22

Q4 '21

Q3 '21

Q2 '21

Q1 '21

Q4 '20

Q3 '20